Metabolite profiling in posttraumatic stress disorder

dc.contributor.authorKarabatsiakis, Alexander
dc.contributor.authorHamuni, Gilava
dc.contributor.authorWilker, Sarah
dc.contributor.authorKolassa, Stephan
dc.contributor.authorRenu, Durairaj
dc.contributor.authorKadereit, Suzanne
dc.contributor.authorSchauer, Maggie
dc.contributor.authorHennessy, Thomas
dc.contributor.authorKolassa, Iris-Tatjana
dc.date.accessioned2015-05-13T08:12:46Z
dc.date.available2015-05-13T08:12:46Z
dc.date.issued2015eng
dc.description.abstractBackground
Traumatic stress does not only increase the risk for posttraumatic stress disorder (PTSD), but is also associated with adverse secondary physical health outcomes. Despite increasing efforts, we only begin to understand the underlying biomolecular processes. The hypothesis-free assessment of a wide range of metabolites (termed metabolite profiling) might contribute to the discovery of biological pathways underlying PTSD.

Methods
Here, we present the results of the first metabolite profiling study in PTSD, which investigated peripheral blood serum samples of 20 PTSD patients and 18 controls. We performed liquid chromatography (LC) coupled to Quadrupole/Time-Of-Flight (QTOF) mass spectrometry. Two complementary statistical approaches were used to identify metabolites associated with PTSD status including univariate analyses and Partial Least Squares Discriminant Analysis (PLS-DA).

Results
Thirteen metabolites displayed significant changes in PTSD, including four glycerophospholipids, and one metabolite involved in endocannabinoid signaling. A biomarker panel of 19 metabolites classifies PTSD with 85% accuracy, while classification accuracy from the glycerophospholipid with the highest differentiating ability already reached 82%.

Conclusions
This study illustrates the feasibility and utility of metabolite profiling for PTSD and suggests lipid-derived and endocannabinoid signaling as potential biological pathways involved in trauma-associated pathophysiology.
eng
dc.description.versionpublished
dc.identifier.doi10.1186/s40303-015-0007-3eng
dc.identifier.ppn432815198
dc.identifier.urihttp://kops.uni-konstanz.de/handle/123456789/30945
dc.language.isoengeng
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectPosttraumatic stress disorder, Metabolite profiling, Mass spectrometry, Biological pathways, Palmitoylethanolamide, Glycerophospholipideng
dc.subject.ddc570eng
dc.titleMetabolite profiling in posttraumatic stress disordereng
dc.typeJOURNAL_ARTICLEeng
dspace.entity.typePublication
kops.citation.bibtex
@article{Karabatsiakis2015Metab-30945,
  year={2015},
  doi={10.1186/s40303-015-0007-3},
  title={Metabolite profiling in posttraumatic stress disorder},
  volume={3},
  journal={Journal of Molecular Psychiatry},
  author={Karabatsiakis, Alexander and Hamuni, Gilava and Wilker, Sarah and Kolassa, Stephan and Renu, Durairaj and Kadereit, Suzanne and Schauer, Maggie and Hennessy, Thomas and Kolassa, Iris-Tatjana},
  note={Article Number: 2}
}
kops.citation.iso690KARABATSIAKIS, Alexander, Gilava HAMUNI, Sarah WILKER, Stephan KOLASSA, Durairaj RENU, Suzanne KADEREIT, Maggie SCHAUER, Thomas HENNESSY, Iris-Tatjana KOLASSA, 2015. Metabolite profiling in posttraumatic stress disorder. In: Journal of Molecular Psychiatry. 2015, 3, 2. eISSN 2049-9256. Available under: doi: 10.1186/s40303-015-0007-3deu
kops.citation.iso690KARABATSIAKIS, Alexander, Gilava HAMUNI, Sarah WILKER, Stephan KOLASSA, Durairaj RENU, Suzanne KADEREIT, Maggie SCHAUER, Thomas HENNESSY, Iris-Tatjana KOLASSA, 2015. Metabolite profiling in posttraumatic stress disorder. In: Journal of Molecular Psychiatry. 2015, 3, 2. eISSN 2049-9256. Available under: doi: 10.1186/s40303-015-0007-3eng
kops.citation.rdf
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/30945">
    <dc:creator>Kadereit, Suzanne</dc:creator>
    <dc:language>eng</dc:language>
    <dcterms:title>Metabolite profiling in posttraumatic stress disorder</dcterms:title>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2015-05-13T08:12:46Z</dcterms:available>
    <dcterms:abstract xml:lang="eng">Background&lt;br /&gt;Traumatic stress does not only increase the risk for posttraumatic stress disorder (PTSD), but is also associated with adverse secondary physical health outcomes. Despite increasing efforts, we only begin to understand the underlying biomolecular processes. The hypothesis-free assessment of a wide range of metabolites (termed metabolite profiling) might contribute to the discovery of biological pathways underlying PTSD.&lt;br /&gt;&lt;br /&gt;Methods&lt;br /&gt;Here, we present the results of the first metabolite profiling study in PTSD, which investigated peripheral blood serum samples of 20 PTSD patients and 18 controls. We performed liquid chromatography (LC) coupled to Quadrupole/Time-Of-Flight (QTOF) mass spectrometry. Two complementary statistical approaches were used to identify metabolites associated with PTSD status including univariate analyses and Partial Least Squares Discriminant Analysis (PLS-DA).&lt;br /&gt;&lt;br /&gt;Results&lt;br /&gt;Thirteen metabolites displayed significant changes in PTSD, including four glycerophospholipids, and one metabolite involved in endocannabinoid signaling. A biomarker panel of 19 metabolites classifies PTSD with 85% accuracy, while classification accuracy from the glycerophospholipid with the highest differentiating ability already reached 82%.&lt;br /&gt;&lt;br /&gt;Conclusions&lt;br /&gt;This study illustrates the feasibility and utility of metabolite profiling for PTSD and suggests lipid-derived and endocannabinoid signaling as potential biological pathways involved in trauma-associated pathophysiology.</dcterms:abstract>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/30945/3/Karabatsiakis_0-288837.pdf"/>
    <dc:creator>Renu, Durairaj</dc:creator>
    <dc:contributor>Wilker, Sarah</dc:contributor>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2015-05-13T08:12:46Z</dc:date>
    <dc:creator>Schauer, Maggie</dc:creator>
    <dc:rights>Attribution 4.0 International</dc:rights>
    <dc:creator>Kolassa, Iris-Tatjana</dc:creator>
    <dc:contributor>Renu, Durairaj</dc:contributor>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:contributor>Karabatsiakis, Alexander</dc:contributor>
    <dc:creator>Kolassa, Stephan</dc:creator>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/30945/3/Karabatsiakis_0-288837.pdf"/>
    <dc:contributor>Hamuni, Gilava</dc:contributor>
    <dcterms:issued>2015</dcterms:issued>
    <dc:creator>Karabatsiakis, Alexander</dc:creator>
    <dc:creator>Hamuni, Gilava</dc:creator>
    <dc:contributor>Kolassa, Stephan</dc:contributor>
    <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/30945"/>
    <dc:contributor>Hennessy, Thomas</dc:contributor>
    <dc:contributor>Schauer, Maggie</dc:contributor>
    <dc:contributor>Kolassa, Iris-Tatjana</dc:contributor>
    <dc:contributor>Kadereit, Suzanne</dc:contributor>
    <dc:creator>Hennessy, Thomas</dc:creator>
    <dc:creator>Wilker, Sarah</dc:creator>
  </rdf:Description>
</rdf:RDF>
kops.description.openAccessopenaccessgoldeng
kops.flag.knbibliographytrue
kops.identifier.nbnurn:nbn:de:bsz:352-0-288837
kops.sourcefieldJournal of Molecular Psychiatry. 2015, <b>3</b>, 2. eISSN 2049-9256. Available under: doi: 10.1186/s40303-015-0007-3deu
kops.sourcefield.plainJournal of Molecular Psychiatry. 2015, 3, 2. eISSN 2049-9256. Available under: doi: 10.1186/s40303-015-0007-3deu
kops.sourcefield.plainJournal of Molecular Psychiatry. 2015, 3, 2. eISSN 2049-9256. Available under: doi: 10.1186/s40303-015-0007-3eng
relation.isAuthorOfPublication9d6a8ea8-0d4f-4e21-b230-fe417e3bb70d
relation.isAuthorOfPublication0db89f95-8fe3-4573-8473-10ae161a335b
relation.isAuthorOfPublication092dcf01-1c52-4490-af23-20e6b268073c
relation.isAuthorOfPublication9d8d5d3f-3ebf-452f-8f3e-15be07bea9ac
relation.isAuthorOfPublication.latestForDiscovery9d6a8ea8-0d4f-4e21-b230-fe417e3bb70d
source.bibliographicInfo.articleNumber2eng
source.bibliographicInfo.volume3eng
source.identifier.eissn2049-9256eng
source.periodicalTitleJournal of Molecular Psychiatryeng
temp.internal.duplicates<p>Keine Dubletten gefunden. Letzte Überprüfung: 05.05.2015 15:46:12</p>deu

Dateien

Originalbündel

Gerade angezeigt 1 - 1 von 1
Vorschaubild nicht verfügbar
Name:
Karabatsiakis_0-288837.pdf
Größe:
580.45 KB
Format:
Adobe Portable Document Format
Karabatsiakis_0-288837.pdf
Karabatsiakis_0-288837.pdfGröße: 580.45 KBDownloads: 286

Lizenzbündel

Gerade angezeigt 1 - 1 von 1
Vorschaubild nicht verfügbar
Name:
license.txt
Größe:
3.59 KB
Format:
Item-specific license agreed upon to submission
Beschreibung:
license.txt
license.txtGröße: 3.59 KBDownloads: 0